Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of ACT-541468 in Insomnia Disorder
jRCT2031200452Phase 3Completed
- Sponsor
- Idorsia
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of daridorexant in Insomnia (3 arms), sponsored by Idorsia. Primary endpoints: Subjective total sleep time and Subjective latency to sleep onset. Started Apr 2021; status: completed.
02
Drugs
daridorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on jRCT2031200452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200452.